INO vs. SGHT, TLSI, ANGO, UTMD, NPCE, RCEL, TMCI, GUTS, TCMD, and PROF
Should you be buying Inovio Pharmaceuticals stock or one of its competitors? The main competitors of Inovio Pharmaceuticals include Sight Sciences (SGHT), TriSalus Life Sciences (TLSI), AngioDynamics (ANGO), Utah Medical Products (UTMD), NeuroPace (NPCE), AVITA Medical (RCEL), Treace Medical Concepts (TMCI), Fractyl Health (GUTS), Tactile Systems Technology (TCMD), and Profound Medical (PROF). These companies are all part of the "surgical & medical instruments" industry.
Inovio Pharmaceuticals (NASDAQ:INO) and Sight Sciences (NASDAQ:SGHT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, community ranking, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.
Sight Sciences has a net margin of -67.18% compared to Inovio Pharmaceuticals' net margin of -16,238.91%. Sight Sciences' return on equity of -44.45% beat Inovio Pharmaceuticals' return on equity.
Inovio Pharmaceuticals has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Comparatively, Sight Sciences has a beta of 2.73, suggesting that its share price is 173% more volatile than the S&P 500.
26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. Comparatively, 55.5% of Sight Sciences shares are owned by institutional investors. 2.5% of Inovio Pharmaceuticals shares are owned by company insiders. Comparatively, 27.1% of Sight Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Inovio Pharmaceuticals had 28 more articles in the media than Sight Sciences. MarketBeat recorded 29 mentions for Inovio Pharmaceuticals and 1 mentions for Sight Sciences. Sight Sciences' average media sentiment score of 1.75 beat Inovio Pharmaceuticals' score of 0.27 indicating that Sight Sciences is being referred to more favorably in the news media.
Inovio Pharmaceuticals presently has a consensus target price of $70.67, suggesting a potential upside of 488.89%. Sight Sciences has a consensus target price of $4.70, suggesting a potential downside of 11.99%. Given Inovio Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Inovio Pharmaceuticals is more favorable than Sight Sciences.
Sight Sciences has higher revenue and earnings than Inovio Pharmaceuticals.
Inovio Pharmaceuticals received 702 more outperform votes than Sight Sciences when rated by MarketBeat users. Likewise, 71.49% of users gave Inovio Pharmaceuticals an outperform vote while only 31.91% of users gave Sight Sciences an outperform vote.
Summary
Sight Sciences beats Inovio Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Inovio Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Inovio Pharmaceuticals Competitors List
Related Companies and Tools
